Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Withdrawn 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Dermatologic 1

Conditions

Breast Neoplasms 8Colorectal Neoplasms 4Pancreatic Neoplasms 3Ovarian Neoplasms 2Lung Neoplasms 2Triple Negative Breast Neoplasms 1Stomach Neoplasms 1Squamous Cell Carcinoma of Head and Neck 1Peripheral Nervous System Diseases 1Pain 1Neoplasms 1Melanoma 1Lymphoma, Non-Hodgkin 1Lung Diseases 1Colorectal Neoplasms, Hereditary Nonpolyposis 1Carcinoma, Transitional Cell 1Carcinoma, Non-Small-Cell Lung 1Carcinoma, Merkel Cell 1Carcinoma, Intraductal, Noninfiltrating 1Cancer Cachexia 1Cachexia 1Breastcancer 1Breast Carcinoma In Situ 1Biliary Tract Neoplasms 1

Interventions

pembrolizumab 300Nivolumab 273Ipilimumab 250aldesleukin 137Cyclophosphamide 135Interleukin-2 105trametinib 82dabrafenib 76Temozolomide 75Dacarbazine 74Vemurafenib 71fludarabine 67fludarabine phosphate 61Biopsy 49binimetinib 47sargramostim 44Radiosurgery 44Bevacizumab 43Paclitaxel 42encorafenib 40incomplete Freund's adjuvant 39atezolizumab 38Radiotherapy 37Cisplatin 36CTLA-4 Antigen 36Carboplatin 35cobimetinib 34Specimen Handling 34Magnetic Resonance Spectroscopy 34Introns 33

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Melanoma × Omacor × Clear all
NCT03167177 2025-02-21

QUILT-3.046: NANT Melanoma Vaccine: Combination Immunotherapy in Subjects With Melanoma Who Have Progressed On or After Chemotherapy and PD-1/PD-L1 Therapy

ImmunityBio, Inc.

Phase 1/2 Withdrawn
Dermatologic

Melanoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡